These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 27100683

  • 1. Use of к-carrageenan, chitosan and Carbopol 974P in extruded and spheronized pellets that are devoid of MCC.
    Valle BL, Omwancha WS, Neau SH, Wigent RJ.
    Drug Dev Ind Pharm; 2016 Nov; 42(11):1903-16. PubMed ID: 27100683
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler.
    Thommes M, Kleinebudde P.
    Eur J Pharm Biopharm; 2006 May; 63(1):59-67. PubMed ID: 16326085
    [Abstract] [Full Text] [Related]

  • 4. Production of chitosan pellets by extrusion/spheronization.
    Steckel H, Mindermann-Nogly F.
    Eur J Pharm Biopharm; 2004 Jan; 57(1):107-14. PubMed ID: 14729086
    [Abstract] [Full Text] [Related]

  • 5. Use of chitosan-alginate as alternative pelletization aid to microcrystalline cellulose in extrusion/spheronization.
    Charoenthai N, Kleinebudde P, Puttipipatkhachorn S.
    J Pharm Sci; 2007 Sep; 96(9):2469-84. PubMed ID: 17286294
    [Abstract] [Full Text] [Related]

  • 6. The preparation by extrusion/spheronization and the properties of pellets containing drugs, microcrystalline cellulose and glyceryl monostearate.
    Chatchawalsaisin J, Podczeck F, Newton JM.
    Eur J Pharm Sci; 2005 Jan; 24(1):35-48. PubMed ID: 15626576
    [Abstract] [Full Text] [Related]

  • 7. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.
    Thommes M, Kleinebudde P.
    Eur J Pharm Biopharm; 2006 May; 63(1):68-75. PubMed ID: 16325384
    [Abstract] [Full Text] [Related]

  • 8. Influence of MCC II fraction and storage conditions on pellet properties.
    Krueger C, Thommes M, Kleinebudde P.
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1039-45. PubMed ID: 23872176
    [Abstract] [Full Text] [Related]

  • 9. The influence of model drugs on the preparation of pellets by extrusion/spheronization: II. Spheronization parameters.
    Tomer G, Podczeck F, Newton JM.
    Int J Pharm; 2002 Jan 01; 231(1):107-19. PubMed ID: 11719019
    [Abstract] [Full Text] [Related]

  • 10. PEO and MPEG in high drug load extruded and spheronized beads that are devoid of MCC.
    Howard MA, Neau SH, Sack MJ.
    Int J Pharm; 2006 Jan 03; 307(1):66-76. PubMed ID: 16253448
    [Abstract] [Full Text] [Related]

  • 11. Importance of the fraction of microcrystalline cellulose and spheronization speed on the properties of extruded pellets made from binary mixtures.
    Kleinebudde P, Schröder M, Schultz P, Müller BW, Waaler T, Nymo L.
    Pharm Dev Technol; 1999 Aug 03; 4(3):397-404. PubMed ID: 10434285
    [Abstract] [Full Text] [Related]

  • 12. Extrusion-Spheronization of blends of carbopol 934 and microcrystalline cellulose.
    Gómez-Carracedo A, Alvarez-Lorenzo C, Gómez-Amoza JL, Martínez-Pacheco R, Souto C, Concheiro A.
    Drug Dev Ind Pharm; 2001 May 03; 27(5):381-91. PubMed ID: 11448045
    [Abstract] [Full Text] [Related]

  • 13. Functionality of cross-linked polyvinylpyrrolidone as a spheronization aid: a promising alternative to microcrystalline cellulose.
    Liew CV, Gu L, Soh JL, Heng PW.
    Pharm Res; 2005 Aug 03; 22(8):1387-98. PubMed ID: 16078149
    [Abstract] [Full Text] [Related]

  • 14. Influence of chitosan type on the properties of extruded pellets with low amount of microcrystalline cellulose.
    Charoenthai N, Kleinebudde P, Puttipipatkhachorn S.
    AAPS PharmSciTech; 2007 Aug 10; 8(3):E64. PubMed ID: 17915814
    [Abstract] [Full Text] [Related]

  • 15. Alternative extrusion-spheronization aids.
    Jain SP, Singh PP, Amin PD.
    Drug Dev Ind Pharm; 2010 Nov 10; 36(11):1364-76. PubMed ID: 20521907
    [Abstract] [Full Text] [Related]

  • 16. Extruded and spheronized beads containing no microcrystalline cellulose: influence of formulation and process variables.
    Agrawal AM, Howard MA, Neau SH.
    Pharm Dev Technol; 2004 Nov 10; 9(2):197-217. PubMed ID: 15202579
    [Abstract] [Full Text] [Related]

  • 17. Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release.
    Ghanam D, Kleinebudde P.
    Int J Pharm; 2011 May 16; 409(1-2):9-18. PubMed ID: 21335073
    [Abstract] [Full Text] [Related]

  • 18. Melt-in-Mouth Multi-particulate System for the Treatment of ADHD: A Convenient Platform for Pediatric Use.
    Patadia J, Tripathi R, Joshi A.
    AAPS PharmSciTech; 2016 Aug 16; 17(4):878-90. PubMed ID: 26392403
    [Abstract] [Full Text] [Related]

  • 19. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization.
    Goyanes A, Martínez-Pacheco R.
    Drug Dev Ind Pharm; 2015 Mar 16; 41(3):362-8. PubMed ID: 24279425
    [Abstract] [Full Text] [Related]

  • 20. Systematic evaluations regarding interparticular mass transfer in spheronization.
    Koester M, Willemsen E, Krueger C, Thommes M.
    Int J Pharm; 2012 Jul 15; 431(1-2):84-9. PubMed ID: 22546294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.